Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.44 |
| ▸ | PPARG | P37231 | 7/20 | 0.44 |
| ▸ | PPARD | Q03181 | 7/20 | 0.44 |
| ▸ | PPARA | Q07869 | 7/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18692016 | 0.83 | — | — | |
| SCHEMBL2786329 | 0.81 | LMNA (0.53) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL18237528 | 0.81 | LMNA (0.53) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL5401035 | 0.79 | LMNA (0.50) | LMNASLC22A6TSHRNFKB1PMP22 | |
| Hydrochloric Acid SCHEMBL11151061 | 0.79 | LMNA (0.50) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL23322447 | 0.77 | LMNA (0.48) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL18227175 | 0.77 | LMNA (0.48) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL7251783 | 0.77 | LMNA (0.48) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL5576557 | 0.77 | AKR1B1 (0.50) | LMNASLC22A6TSHRNFKB1PMP22 | |
| Hydrochloric Acid SCHEMBL9182562 | 0.75 | LMNA (0.46) | LMNASLC22A6TSHRNFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11497757-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | BLINKBIO INC (US) | 2018-07-19 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-7157543-B2 | Block polyorganosiloxane block organomer polymers and release agents | EASTMAN KODAK COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050182206-A1 | Block polyorganosiloxane block organomer polymers and release agents | KODAK PHILIPPINES LTD. | 2005-08-18 | — | — | US | disclosed |
| US-6894137-B2 | Block polyorganosiloxane block organomer polymers and release agents | EASMAN KODAK COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030232948-A1 | Block polyorganosiloxane block organomer polymers and release agents | BANK OF AMERICA, N.A., AS AGENT | 2003-12-18 | — | — | US | disclosed |
| WO-1992008758-A1 | SILICONE SURFACE-MODIFIED AMMONIUM POLYPHOSPHATE | PPG INDUSTRIES, INC. (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | LMNA 3473/4885SLC22A6 488/4885TSHR 2393/4885 |
| US-11497757-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | LMNA 1211/4885SLC22A6 2690/4885TSHR 3437/4885 |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | LMNA 1211/4885SLC22A6 2690/4885TSHR 3437/4885 |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | CD47, CD4, BST2 | LMNA 1211/4885SLC22A6 2690/4885TSHR 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.